Nicox S.A. (0RCQ.L)
| Previous close | 3.1652 |
| Open | 3.1600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.1450 - 3.1600 |
| 52-week range | 3.1450 - 3.1600 |
| Volume | 628 |
| Avg. volume | N/A |
| Market cap | 91.063M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5370 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Number of voting rights as of July 31, 2021
Nicox SA Société anonyme with a registered capital of € 37,125,385 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On August 2, 2021, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of July 31, 2021Total number of shares composing the share capital37,125,385Total
- Globe Newswire
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update
Press ReleaseNicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update Lead value drivers are 100% ownership of NCX 470 and NCX 4251 in the U.S., Europe and JapanVYZULTA® and ZERVIATE® prescriptions in the U.S. increased by 21% and 712% respectively in Q2 2021 compared to Q2 2020 Cash of €36.5 million on June 30, 2021 sufficient for the Company to meet its current requirements for the next twelve months July 16, 2021 – release at 7:30 am CET Sophia Antipolis, Fran
- Globe Newswire
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board
Press ReleaseNicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory BoardJuly 13, 2021 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, M.D., Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego, and Sanjay G. A
